201 related articles for article (PubMed ID: 14990727)
21. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
Brett IC; Johansson BE
Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
[TBL] [Abstract][Full Text] [Related]
22. Recombinant influenza A viruses harboring optimized dicistronic NA segment with an extended native 5' terminal sequence: induction of heterospecific B and T cell responses in mice.
Vieira Machado A; Naffakh N; Gerbaud S; van der Werf S; Escriou N
Virology; 2006 Feb; 345(1):73-87. PubMed ID: 16271378
[TBL] [Abstract][Full Text] [Related]
23. Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection.
Kim YJ; Ko EJ; Kim MC; Lee YN; Kim KH; Jung YJ; Kang SM
Biochem Biophys Res Commun; 2017 Nov; 493(1):393-398. PubMed ID: 28887040
[TBL] [Abstract][Full Text] [Related]
24. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
Galarza JM; Latham T; Cupo A
Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
[TBL] [Abstract][Full Text] [Related]
25. Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
Fang F; Cai XQ; Chang HY; Wang HD; Yang ZD; Chen Z
Acta Virol; 2008; 52(2):107-12. PubMed ID: 18564897
[TBL] [Abstract][Full Text] [Related]
26. A DNA vaccine expressing PB1 protein of influenza A virus protects mice against virus infection.
Košík I; Krejnusová I; Práznovská M; Poláková K; Russ G
Arch Virol; 2012 May; 157(5):811-7. PubMed ID: 22294447
[TBL] [Abstract][Full Text] [Related]
27. Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus.
Kash JC; Basler CF; García-Sastre A; Carter V; Billharz R; Swayne DE; Przygodzki RM; Taubenberger JK; Katze MG; Tumpey TM
J Virol; 2004 Sep; 78(17):9499-511. PubMed ID: 15308742
[TBL] [Abstract][Full Text] [Related]
28. Influenza virus neuraminidase (NA): a target for antivirals and vaccines.
Jagadesh A; Salam AA; Mudgal PP; Arunkumar G
Arch Virol; 2016 Aug; 161(8):2087-94. PubMed ID: 27255748
[TBL] [Abstract][Full Text] [Related]
29. Generation of influenza A viruses with chimeric (type A/B) hemagglutinins.
Horimoto T; Takada A; Iwatsuki-Horimoto K; Hatta M; Goto H; Kawaoka Y
J Virol; 2003 Jul; 77(14):8031-8. PubMed ID: 12829842
[TBL] [Abstract][Full Text] [Related]
30. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge.
Tompkins SM; Lin Y; Leser GP; Kramer KA; Haas DL; Howerth EW; Xu J; Kennett MJ; Durbin RK; Durbin JE; Tripp R; Lamb RA; He B
Virology; 2007 May; 362(1):139-50. PubMed ID: 17254623
[TBL] [Abstract][Full Text] [Related]
31. [Mutations in the genes coding for hemagglutinin and neuraminidase in cold-adapted variants of the influenza virus A/Leningrad/134/57 (H2N2)].
Medvedeva TE; Kudriavtseva VK; Zhikhareva IV; Romashkina VV; Aleksandrova GI; Klimov AI
Vopr Virusol; 1991; 36(2):96-100. PubMed ID: 1882532
[TBL] [Abstract][Full Text] [Related]
32. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
Kingstad-Bakke B; Kamlangdee A; Osorio JE
Vaccine; 2015 Sep; 33(39):5155-62. PubMed ID: 26271828
[TBL] [Abstract][Full Text] [Related]
33. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
[TBL] [Abstract][Full Text] [Related]
34. Introduction of foreign sequences into the genome of influenza A virus.
García-Sastre A; Percy N; Barclay W; Palese P
Dev Biol Stand; 1994; 82():237-46. PubMed ID: 7525392
[TBL] [Abstract][Full Text] [Related]
35. Live Attenuated Influenza Vaccine contains Substantial and Unexpected Amounts of Defective Viral Genomic RNA.
Gould PS; Easton AJ; Dimmock NJ
Viruses; 2017 Sep; 9(10):. PubMed ID: 28934167
[TBL] [Abstract][Full Text] [Related]
36. Development and characterization of a live attenuated influenza B virus vaccine candidate.
Seo SU; Byun YH; Lee EY; Jung EJ; Jang YH; Kim HA; Ha SH; Lee KH; Seong BL
Vaccine; 2008 Feb; 26(7):874-81. PubMed ID: 18207290
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].
Smolonogina TA; Desheva IuA; Rekstin AR; Mironov AN; Rudenko LG
Vopr Virusol; 2013; 58(6):31-5. PubMed ID: 24772644
[TBL] [Abstract][Full Text] [Related]
38. The relative amount of an influenza A virus segment present in the viral particle is not affected by a reduction in replication of that segment.
Bergmann M; Muster T
J Gen Virol; 1995 Dec; 76 ( Pt 12)():3211-5. PubMed ID: 8847532
[TBL] [Abstract][Full Text] [Related]
39. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.
Kittel C; Ferko B; Kurz M; Voglauer R; Sereinig S; Romanova J; Stiegler G; Katinger H; Egorov A
J Virol; 2005 Aug; 79(16):10672-7. PubMed ID: 16051859
[TBL] [Abstract][Full Text] [Related]
40. Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines.
Nogales A; DeDiego ML; Topham DJ; Martínez-Sobrido L
J Virol; 2016 Jul; 90(14):6291-6302. PubMed ID: 27122587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
